Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Revealing Protective Immunity to Influenza Using Systems Immunology
NCT06501963Phase 4Completed
- Sponsor
- Emory University
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of live attenuated influenza vaccine in influenza, sponsored by Emory University. Primary endpoint: Quantification of Antibody Titers at 30 days. Started Oct 2024; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06501963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501963.